Related Experiment Video
Updated: Jun 9, 2026
09:31
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Lecanemab and amyloid-related imaging abnormalities: Real-world data from a single center experience
Alexander Wallace1, Oliver Zhou2,3, Minh-Nguyet Hoang2,3
1University of Iowa Hospitals and Clinics Iowa City Iowa USA.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|June 8, 2026
Summary
Real-world data show lecanemab (lecanemab) is safe and effective for Alzheimer's disease, similar to clinical trials. The study focused on amyloid-related imaging abnormalities (ARIA) in routine care.
Area of Science:
- Neurology
- Pharmacology
- Clinical Research
Background:
- Lecanemab (lecanemab) has shown safety and efficacy in clinical trials.
- Real-world clinical data on lecanemab are limited, particularly regarding safety.
- Amyloid-related imaging abnormalities (ARIA) are a key safety concern.
Purpose of the Study:
- To evaluate the real-world safety and efficacy of lecanemab.
- To specifically assess amyloid-related imaging abnormalities (ARIA) in patients receiving lecanemab.
- To compare real-world findings with data from the Clarity-AD clinical trial.
Main Methods:
- Retrospective chart review of 146 patients treated with lecanemab.
- Patients were treated according to appropriate-use recommendations.
- Data collected from a specialty memory center clinic.
Main Results:
- Real-world safety and efficacy align with Clarity-AD trial results.
- 23% of patients discontinued lecanemab treatment; others completed at least 12 months.
- A trend of increased ARIA edema/effusion (ARIA-E) was noted with higher mean arterial pressure, and mean amyloid clearance was -90.6 at 18 months.
Conclusions:
- Lecanemab is safe when used per appropriate-use recommendations, consistent with clinical trial findings.
- Real-world data support lecanemab's safety profile.
- Further real-world data collection is needed for comprehensive evaluation of lecanemab's long-term safety and efficacy.
